Time filter

Source Type

Ymittos Athens, Greece

Vlachantoni I.-T.,National and Kapodistrian University of Athens | Gerakopoulou P.,National and Kapodistrian University of Athens | Amfilochiou A.,Sleep Study Unit | Dessypris N.,National and Kapodistrian University of Athens | Petridou E.T.,National and Kapodistrian University of Athens
Pneumon | Year: 2015

Aim: To evaluate the prevalence of morning and day sleepiness and obstructive sleep apnea syndrome (OSAS) among taxi drivers of the Athens airport and to examine the factors that may influence a taxi driver’s decision to participate in screening. Methods: Demographic, sleep and work-related data were obtained for 840 professional drivers through a self-administered questionnaire based on Berlin scale variables; individuals identified at high OSAS risk were thereafter identified and offered cost-free nocturnal pulse-oximeter and sleep study. A qualitative study was subsequently conducted among those who declined participation aiming to identify facilitating factors and barriers to attend screening and diagnosis. Results: One out of 4 participants was identified as high-risk, a ~80% provided further contact details, whereas ~75% of those contacted declined further participation; 17 out of the 22 who attended the diagnosis process suffered OSA. Drivers who declined participation were more likely to smoke, snore loudly and work on night-shifts. Non-participants did not perceive personal health as a priority, acknowledged the need for preventive healthcare but valued its practical uptake as difficult. Exposure to high stress levels along with struggle to combat financial survival was highly prioritized as a barrier, whereas suggestions for facilitating factors to improve participation included on-site examination and monetary incentives. Conclusions: Drivers were found to be high-risk for OSA but a hard to reach professional group unaware about on the associated personal and societal risk encountered. Increase efforts to raise awareness and tailoring of the medical evaluation process to individual needs are of paramount importance. © 2015, Technogramma. All rights reserved. Source

Tsekou H.,Sleep Study Unit | Angelopoulos E.,National and Kapodistrian University of Athens | Paparrigopoulos T.,Sleep Study Unit | Paparrigopoulos T.,National and Kapodistrian University of Athens | And 5 more authors.
Journal of Clinical Neurophysiology | Year: 2015

Purpose: Clozapine is an atypical neuroleptic agent, effective in treating drug-resistant schizophrenia. The aim of this work was to investigate overall sleep architecture and sleep spindle morphology characteristics, before and after combination treatment with clozapine, in patients with drug-resistant schizophrenia who underwent polysomnography. Methods: Standard polysomnographic techniques were used. To quantify the sleep spindle morphology, a modeling technique was used that quantifies time-varying patterns in both the spindle envelope and the intraspindle frequency. Results: After combination treatment with clozapine, the patients showed clinical improvement. In addition, their overall sleep architecture and, more importantly, parameters that quantify the time-varying sleep spindle morphology were affected. Specifically, the results showed increased stage 2 sleep, reduced slow-wave sleep, increased rapid eye movement sleep, increased total sleep time, decreased wake time after sleep onset, as well as effects on spindle amplitude and intraspindle frequency parameters. However, the above changes in overall sleep architecture were statistically nonsignificant trends. Conclusions: The findings concerning statistically significant effects on spindle amplitude and intraspindle frequency parameters may imply changes in cortical sleep EEG generation mechanisms, as well as changes in thalamic pacing mechanisms or in thalamo-cortical network dynamics involved in sleep EEG generation, as a result of combination treatment with clozapine. Significance: Sleep spindle parameters may serve as metrics for the eventual development of effective EEG biomarkers to investigate treatment effects and pathophysiological mechanisms in schizophrenia. © 2014 by the American Clinical Neurophysiology Society. Source

Discover hidden collaborations